#SFHS2608517VNotice on the Prices of Pharmaceutical Specialties
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
This law sets the prices for specific pharmaceutical products in France, namely OFEV 25 mg capsules, produced by Boehringer Ingelheim France. The fixed prices for these medications are part of a convention between the economic committee of health products and the pharmaceutical company. The new prices become effective four days after being published in France's official journal.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Fixed prices for OFEV 25 mg capsules in France
- Agreement between health product economic committee and Boehringer Ingelheim France
- Prices effective four days post-publication in the official journal
Obligations
What this law requires
Set and maintain the fixed price of OFEV 25 mg (nintédanib) capsules, soft (B/120) at €1,325.87 PFHT and €1,455.76 PPTTC
Set and maintain the fixed price of OFEV 25 mg (nintédanib) capsules, soft (B/180) at €1,325.87 PFHT and €1,455.76 PPTTC
Apply the new fixed prices effective from the fourth day following publication in the Journal officiel de la République française
Ensure pricing compliance with the convention agreement between the Comité économique des produits de santé and Boehringer Ingelheim France